News & analysis on the clinical development and manufacture of large molecule drugs
Regeneron, Edward Cox
By Vassia Barba
- Last updated on
After having spent over 20 years at the FDA, Edward Cox resigned from the position of director of the Office of Antimicrobial Products (OAP), which he held for 12 years, to make the jump into the biotech industry.
A spokesperson for Regeneron confirmed to BioPharma-Reporter that Cox had been appointed VP of regulatory affairs at the company, beginning his new role on August 26. Cox is reporting to the SVP of regulatory affairs, Ned Braunstein.
During his service at the FDA, Cox was responsible for divisions that reviewed antibacterial, antiviral, antifungal, antiparasitic and antimycobacterial products.